As late as August 3, MannKind Corp (MNKD-$6.34) predicted a successful outcome to negotiations with Big Pharma to co-market its lead product candidate, the inhaled insulin product AFRESA. Unfortunately, after burning through more than $1.4 billion to develop the inhaler, still no deal. Notwithstanding credibility issues, the question remains whether the pulmonary route of delivering insulin is finished in the eyes of the FDA — or if MannKind’s inability to secure a marketing deal at this time with a deeper-pocketed pharmaceutical house was nothing more than financial posturing by the company to secure a better deal. Read More at BNET PHARMA….
Editor David J Phillips does not hold a financial interest in any stocks mentioned n this article. The 10Q Detective has a Full Disclosure Policy.
